JAK2 as Predictor of Therapeutic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib

Table 1

Patient baseline characteristics.

Variable	n = 40
Age, years (mean ± SD)	40 ± 11
Sex, n (%)
Male	24 (60)
Female	16 (40)
Spleen size, cm (mean ± SD)	8 ± 3
Laboratory parameters, median (range)
Hemoglobin (g/dL)	9.5 ± 2.6
White cell count (/μL)	111,585 (20,390–498,470)
Peripheral blood basophils (%)	1 (0–8)
Eosinophils (%)	1 (0–5)
Platelet count (x10^3/μL)	294 (31–1,123)
Peripheral blood blasts (%)	8 (2–20)
Sokal risk groups, n (%)
Low (<0.8)	17 (42.5)
Intermediate (0.8–1.2)	7 (17.5)
High (>1.2)	16 (40.0)
Hasford risk groups, n (%)
Low (≤780)	12 (30.0)
Intermediate (781–1,480)	15 (37.5)
High (>1,480)	13 (32.5)
EUTOS risk groups, n (%)
Low risk (≤87)	38 (95.0)
High risk (>87)	2 (5.0)